The Interplay Between Sleep and Bipolar Disorder - Pharmacist

Target Audience:

Physicians, pharmacists, and other health care professionals with an interest in sleep and bipolar disorder.

Statement of Need

The importance of sleep in the treatment of chronic mood disorders is not a new concept. Nearly a century ago, Kraepelin, one of the founders of modern scientific psychiatry, wrote: “The attacks of manic-depressive insanity are invariably accompanied by all kinds of bodily changes. By far the most striking are the disorders of sleep and general nourishment.”

Since these words were shared by Kraepelin, the volume of accumulated literature on the interplay between sleep and mood has substantially increased. In the scientific realm, much is known about the bidirectional relationship of mood and sleep. Clinically, both the influence of disturbed sleep on manic episodes related to bipolar disorder and persistent sleep disturbances in unipolar and bipolar depression highlight the need for clinicians to use a systematic approach in managing sleep complaints in patients with bipolar disorder.

This neuroscienceCME Snack™ activity highlights the critical, clinical steps involved in providing optimal care to patients with bipolar disorder who have hypersomnia, sleep loss, or disturbed sleep.

  1. Gruber J, Miklowitz DJ, Harvey AG, et al. Sleep matters: sleep functioning and course of illness in bipolar disorder. J Affect Disord. 2011;134(1-3):416-420. PMID: 21683450.
  2. Talbot LS, Stone S, Gruber J, Hairston IS, Eidelman P, Harvey AG. A test of the bidirectional association between sleep and mood in bipolar disorder and insomnia. J Abnorm Psychol. 2012;121(1):39-50. PMID: 21842957.

Activity Goal

This educational activity centers on the CMEO Make One Change Statement. This statement is crafted from pertinent quality measures or clinical guidelines as a performance challenge to all participants. The Make One Change Statement for this activity is: 

Initiate and maintain a solid communication dynamic with patients with bipolar depression so that they understand the role of sleep in bipolar disorder outcomes.

Unlabeled Use Disclosure

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

 CME Outfitters, LLC, Teva Pharmaceuticals, and the faculty do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.

 Questions about this activity? Call us at 877.CME.PROS (877.263.7767).

Accreditation:

CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Post-tests, credit request forms, and activity evaluations must be completed online (80% pass rate required).

Credit Designation:
CME Outfitters designates this continuing education activity for 0.25 contact hours (0.025 CEUs) of the Accreditation Council for Pharmacy Education.

Universal Activity Number: 0376-0000-13-027-H01-P (recorded programs)
Activity Type: knowledge-based

Credit Designation:

CME Outfitters, LLC designates this continuing education activity for 0.25 contact hour (0.[+ADD NUMBER+] CEUs) of the Accreditation Council for Pharmacy Education. Universal Program Number: 0376-0000-12-017-H01-P

Activity Type: knowledge-based

Faculty Listing:

W. Vaughn McCall, MD, MS
Case Distinguished Chair
Department of Psychiatry and Health Behavior
Medical College of Georgia/Georgia Regents University
Augusta, GA
 
Thomas Roth, PhD
Director of Research and Division Head
Sleep Disorders and Research Center
Henry Ford Health System
Detroit, MI

Objectives:

  • Accurately and routinely administer validated questionnaires to improve detection of sleep disturbances and other residual symptoms in patients with bipolar depression.
  • Employ evidence-based and measure-based care strategies to optimize outcomes for patients with bipolar depression.

Financial Disclosure:

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. McCall has disclosed that he has received grant support from Merck and National Institute of Mental Health.He serves as a scientific advisor for Luitpold Pharmaceuticals, Inc.

Dr. Roth has disclosed that he has received grant support from Apnex Medical, Inc. and Merck & Co. He serves as a consultant for Consultant: Abbott Laboratories; AstraZeneca Pharmaceutical, Inc.; Intec Pharma ltd.; Jazz Pharmaceuticals plc; Merck & Co., Inc.; Neurocrine Biosciences, Inc.; Proctor and Gamble; Pfizer Inc; Purdue Pharma L.P.; Sepracor Inc.; Shire Pharmaceuticals Inc.; Somaxon Pharmaceuticals, Inc.; Somnus Therapeutics Inc; Steady Sleep Rx Co.; Transcept Pharmaceuticals, Inc.

Tony Graham, MD (peer review) has no disclosures to report. 

Joy Bartnett Leffler, MLA, NASW, CSE (planning committee) has no disclosures to report.

Sandra Haas Binford, MAEd (planning committee) has no disclosures to report.

Sharon Tordoff, CCMEP (planning committee) has no disclosures to report.